Lutris Pharma's LUT014 Gel Shows Promise in Treating Acne Rash Linked to Cancer Therapies At the AACR Annual Meeting 2025, Lutris Pharma unveiled promising data for its LUT014 gel, demonstrating efficacy in treating acneiform rash in cancer patients, enhancing care outcomes.

Lutris Pharma's LUT014 Gel Shows Promise in Treating Acne Rash Linked to Cancer Therapies #USA #Tel_Aviv #Lutris_Pharma #LUT014 #BRAF_Inhibitor